OncoBEAM™ EGFR

  • The OncoBEAM™ EGFR test is a bead-based digital PCR approach (also called BEAMing Digital PCR) allowing for the detection of up to 10 different mutations within the EGFR gene from one single sample.
  • Mutations covered:
    E746_ A750del, E746_S752>V, L747_A750>P, L747_T751del, L747_P753>S, T790M, C797S*, L858R

Documents

All
  • All
  • Brochure
Documents

The epidermal growth factor receptor (EGFR) belongs to the family of receptor tyrosine kinases(RTKS). The EGFR signaling pathway is one of the most important pathways that regulate growth,survival, proliferation, and differentiation in mammalian cells.

NSCLC tumors that harbor activating EGFR mutations represent a clinically distinct subtype of disease associated with better prognosis due to their increased sensitivity to tyrosine kinase inhibitors (TKIs)such as erlotinib, afatinib and gefitinib.1‐3 However, in most patients disease ultimately progresses with approximately 60% of patients developing acquired resistance from the T790M mutation.4‐8 Several third generation EGFR inhibitors that inhibit EGFR with T790M have been developed leading to remissions in a majority of these cancers.9,10 Despite these promising initial results, development of resistance to these drugs has been already shown. Very recently, the EGFR C797S mutation has been identified as one of the keydrivers of resistance mechanisms specific to third generation EGFR inhibitors.11‐13

* FOR RESEARCH USE ONLY. Not for use in diagnostic procedures.

DOWNLOAD BROCHURE
OncoBEAM EGFR

BACK TO LIST

Mutations

Mutations

Clinical Relevance

Clinical Relevance

  • NSCLC
Test Details

Test Details

Turn around times

  • Batch analysis <4 weeks
  • Single samples < 10 days

Sample Requirements

  • Serum/Plasma
    ≥ 2 ml
  • Whole blood
    10 ml
  • FFPE/Frozen Tissue
    3 sections at 5 μm
References

References

  1. Mok TS et al. (2009) N Engl J Med. 361(10):947‐957.
  2. Rosell R. et al. (2012) Lancet Oncol. 13, 239–246.
  3. Sequist L. V. et al. (2013) J.Clin. Oncol. 31, 3327–3334.
  4. Yu H. A. et al. (2013) Clin. Cancer Res. 19, 2240–2247.
  5. Maemondo M et al (2010) N Engl J Med. 362(25):2380‐2388.
  6. Mitsudomi T et al; (2010) Lancet Oncol. 11(2):121‐128.
  7. Rosell R et al (2012) Lancet Oncol. 13(3):239‐246.
  8. Zhou C et al. (2011) Lancet Oncol. 12(8):735‐742.
  9. Cross DAE et al. (2014) Cancer Discovery. 4(9):1046‐61J.
  10. anne PA et al. (2015) N Engl J Med 372:1689–1699.
  11. Thress KS et al. (2015) Nat Med. 21(6): 560–562. 
  12. Yu HA et al. (2015) JAMA Oncol. 1:982–984.
  13. Song HN et al. (2015) J Thorac Oncol. pii: S1556‐0864(15)00209‐9.
Contact

Sales Support

info@sysmex-inostics.com

Create Pdf